<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0041234" disease_type="Disease or Syndrome" abbrv="">Chagas disease</z:e> is the principal cause of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001635'>heart failure</z:hpo> in areas where the disease is endemic </plain></SENT>
<SENT sid="1" pm="."><plain>The medical treatment is the same recommended for non-<z:e sem="disease" ids="C0041234" disease_type="Disease or Syndrome" abbrv="">Chagas disease</z:e> patients </plain></SENT>
<SENT sid="2" pm="."><plain>There is no evidence-based medicine support for device therapy in <z:e sem="disease" ids="C0041234" disease_type="Disease or Syndrome" abbrv="">Chagas disease</z:e> <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Cardiac resynchronization therapy is recommended for <z:e sem="disease" ids="C0041234" disease_type="Disease or Syndrome" abbrv="">Chagas disease</z:e> <z:hpo ids='HP_0001635'>heart failure</z:hpo> patients with intraventricular conduction disturbances, mainly for those with <z:hpo ids='HP_0011713'>left bundle branch block</z:hpo>, and in advanced <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo> refractory to targeted medical treatment, although this therapy is still polemic in <z:e sem="disease" ids="C0041234" disease_type="Disease or Syndrome" abbrv="">Chagas disease</z:e> <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Implantable cardioverter-defibrillator (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>) therapy is indicated to <z:e sem="disease" ids="C0041234" disease_type="Disease or Syndrome" abbrv="">Chagas disease</z:e> patients with left ventricular ejection fraction &lt;30% for primary prevention of <z:hpo ids='HP_0001645'>sudden cardiac death</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy is offered to patients for secondary prevention of <z:hpo ids='HP_0001645'>sudden cardiac death</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Patients with moderate left ventricular dysfunction and inducible <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> at electrophysiological testing should receive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy </plain></SENT>
</text></document>